Skip to content

K-Stock Briefing

https://kstockbriefing.com

  • About Us
  • Weekly News
  • IR Room
  • RESEARCH
  • Disclosures
    • Semiconductors
    • Bio & Healthcare
    • Defense
    • Shipbuilding
    • Automotive
  • Toggle search form

[Disclosure] Hana Micron (067310) – Decision on Cash/In-Kind Dividend / 2024-03-13

Posted on March 13, 2024August 2, 2026 By K-STOCK Editor No Comments on [Disclosure] Hana Micron (067310) – Decision on Cash/In-Kind Dividend / 2024-03-13

Fact Source: Financial Supervisory Service DART

💡 Executive Summary

Hana Micron decided on a year-end cash dividend of KRW 50 per common share (dividend yield of 0.17%), totaling approximately KRW 2.40 billion for FY2023.

📊 Key Disclosure Content & Financial Figures Summary

  1. Company Name: Hana Micron Inc.
  2. Dividend Category & Type: Year-end Dividend / Cash Dividend (Non-differential)
  3. Dividend per Share: KRW 50 per common share
  4. Dividend Yield: 0.17% for common shares (Based on average share price of KRW 28,988)
  5. Total Dividend Amount: KRW 2,398,992,700 (Total eligible shares: 47,979,854 shares)
  6. Record Date for Dividend: December 31, 2023
  7. Scheduled Date of Shareholders’ Meeting: March 28, 2024
  8. Scheduled Dividend Payment Date: To be paid within 1 month following approval at the General Shareholders’ Meeting
  9. Board Resolution Date: March 13, 2024 (1 Outside Director attended, Auditor attended)

📝 Editor’s Comment (Key Follow-up Checkpoint)

📌 Verification of Year-End Cash Dividend Scale and Shareholder Approval Schedule

This disclosure announces the decision to pay a year-end cash dividend for FY2023. Checking the dividend amount per share (KRW 50) and total dividend payout (approx. KRW 2.40 billion), as well as tracking the final approval at the Annual General Meeting on March 28, 2024, and the subsequent payment timeline within one month is necessary. Further details can be verified through this disclosure and the Korea Exchange KIND system.

📢 Disclaimer & Source Information

Source: This content was structured and regenerated based on official data submitted to the Financial Supervisory Service’s Data Analysis, Retrieval and Transfer System (DART).

Investment Disclaimer: This content is provided solely for information purposes and linguistic reference. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific securities. All investment decisions and financial risks rest solely with the investor.

Contact: For compliance inquiries or copyright-related issues, please contact ksb220805@gmail.com.

Search by
Company Name or Stock Ticker.
Disclosures, Semiconductors

Post navigation

Previous Post: [Disclosure] Hana Micron (067310) – Change in Revenue or Income Structure Exceeding 30% (15% for Large Corporations) / 2024-03-13
Next Post: [Disclosure] HPSP (403870) – Report on Reason for Holding General Meeting of Shareholders on Concentrated Date / 2024-03-14

Related Posts

[Disclosure] HPSP (403870) – Setting of Record Date or Period for Closure of Shareholders Register / 2025-09-26 Semiconductors
[Disclosure] Jeju Semiconductor (080220) – Securities Issuance Results (Voluntary Disclosure) / 2026-03-23 Semiconductors
[Disclosure] Hanwha Systems (272210) – Corrected Filing for Subsidiary Hanwha Philly Shipyard Inc. Capital Increase (Payment Date Revised to Dec 23, 2025) Disclosures
[Disclosure] Hanmi Semiconductor (042700) – Submission of Audit Report / 2025-03-13 Semiconductors
[Disclosure] LEENO Industrial (058470) – Change in Profit/Loss Structure over 30% (15% for Large Companies) / 2026-02-10 Disclosures
[Disclosure] Celltrion (068270) – Approval of Phase 3 Clinical Trial Plan for CT-P51 (Keytruda Biosimilar) in Europe (Part 1 & 2) / 2024-12-13 Disclosures

Leave a Reply Cancel reply

You must be logged in to post a comment.

  • [Disclosure] Hanwha Ocean (042660) – Clarification on Rumors or Reports (Unconfirmed) / 2026-08-07August 7, 2026
  • [Disclosure] ALTEOGEN (196170) – Exclusive License Agreement for Recombinant Human Hyaluronidase Product ALT-B4 / 2026-08-05August 5, 2026
  • [Disclosure] ALTEOGEN (196170) – Ex-Rights (Bonus Issue) / 2026-08-04August 4, 2026
  • [Disclosure] ALTEOGEN (196170) – Market Measures on Stock Futures and Options (Bonus Issue) / 2026-08-04August 4, 2026
  • [Disclosure] Celltrion (068270) – CT-P44 (Darzalex Biosimilar) Korea Phase 3 Clinical Trial Plan Amendment Application / 2026-08-03August 3, 2026

Copyright © 2026 K-Stock Briefing.

Powered by PressBook Grid Dark theme